Lyons D, Fowler G, Petrie J C, Webster J
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill.
Br J Clin Pharmacol. 1993 Sep;36(3):271-3. doi: 10.1111/j.1365-2125.1993.tb04229.x.
This study was designed to determine if GR 32191 a thromboxane A2 receptor antagonist, would lower blood pressure in patients with hypertension and renal artery stenosis. Eight patients with unilateral atheromatous renal artery stenosis and hypertension were studied in a double-blind, single dose, placebo controlled, crossover study. The results show that, GR 32191, given orally, in doses of 20 mg and 40 mg, does not reduce the blood pressure to any clinically important degree.
本研究旨在确定血栓素A2受体拮抗剂GR 32191是否能降低高血压合并肾动脉狭窄患者的血压。在一项双盲、单剂量、安慰剂对照的交叉研究中，对8例单侧动脉粥样硬化性肾动脉狭窄合并高血压患者进行了研究。结果显示，口服20毫克和40毫克剂量的GR 32191，并未使血压降低到任何具有临床意义的程度。
